Home » Stocks » IMMU

Immunomedics, Inc. (IMMU)

Oct 23, 2020 - IMMU was delisted after being acquired by GILD
Stock Price: $87.86 USD 0.00 (0.00%)
Updated Oct 23, 2020 4:00 PM EDT
Market Cap 20.31B
Revenue (ttm) 20.37M
Net Income (ttm) -353.41M
Shares Out 225.31M
EPS (ttm) -1.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day Oct 23, 2020
Last Price $87.86
Previous Close $87.86
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 87.59 - 87.93
Day's Volume 0
52-Week Range 8.80 - 87.93

News

Hide News
Insider Monkey - 2 months ago

While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, virus news and stimulus talks, many smart money investors are starting to ge...

Business Wire - 2 months ago

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire Immunomedics, Inc. (Nasdaq: IMMU) f...

Other stocks mentioned: GILD
PRNewsWire - 3 months ago

LEIDEN, Netherlands, Oct. 20, 2020 /PRNewswire/ -- ProteoNic BV, a leading provider of technology and services in the field of production of biologics, today announced it has licensed its prem...

Zacks Investment Research - 3 months ago

Immunomedics' (IMMU) lead product candidate, Trodelvy, gets FDA orphan drug status for the treatment of adult and pediatric patients with glioblastoma.

GlobeNewsWire - 3 months ago

MORRIS PLAINS, N.J., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug con...

Investopedia - 3 months ago

These are the stocks with the best value, fastest growth, and most momentum for October 2020.

Other stocks mentioned: ACI, ARD, BERY, BHF, BPYU, CRM, LVGO, MRNA, NLOK, NRG, QDEL, TSLA, ZM
GuruFocus - 3 months ago

Some investors are questioning whether the $21 billion Gilead Sciences Inc. (NASDAQ:GILD) agreed to pay for Immunomedics Inc. (NASDAQ:IMMU) last week was too much.

Other stocks mentioned: GILD
Investopedia - 3 months ago

These are the healthcare stocks with the best value, fastest growth, and most momentum for October 2020.

Other stocks mentioned: BIIB, BIO, CVS, LVGO, MRNA, PODD, PRGO, QDEL
Zacks Investment Research - 3 months ago

As of late, it has definitely been a great time to be an investor Immunomedics.

The Motley Fool - 4 months ago

Results from a study of Trodelvy presented over the weekend suggest Gilead Sciences' $21 billion buyout offer was a smart move.

Zacks Investment Research - 4 months ago

Immunomedics (IMMU) releases data from different cancer studies on its lead drug, Trodelvy.

PRNewsWire - 4 months ago

SAN DIEGO, Sept. 20, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Immunomedics Inc. (NASDAQ: IMMU) ("Imm...

GlobeNewsWire - 4 months ago

Trodelvy achieves a 27 percent overall response rate and a 5.9-month median duration of response in heavily-pretreated patients with metastatic urothelial cancer (mUC)

GlobeNewsWire - 4 months ago

Trodelvy significantly red uced the risk of death by 52 percent, with a median overall survival (OS) of 12.1 months compared to 6.7 months for standard single-agent chemothera py

PRNewsWire - 4 months ago

NEW YORK, Sept. 18, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in N...

The Motley Fool - 4 months ago

Find out what's behind their big run-ups to see if they can make it happen again.

Other stocks mentioned: MRNS, VXRT
GlobeNewsWire - 4 months ago

Results include partial responses in small cohort of patients with brain metastasis from breast cancer (BMBC) and recurrent glioblastoma (rGBM) Results include partial responses in small cohor...

InvestorPlace - 4 months ago

It’s an exciting time for mergers and acquisitions in some of the hottest sectors -- including software, cloud services, artificial intelligence and health care. Here are four major mergers to...

Other stocks mentioned: GILD, MRK, NVDA, ORCL, SGEN
Zacks Investment Research - 4 months ago

After tumbling to the lowest level in more than a decade in the second quarter, global M&A activity gathered steam in September following the flurry of latest deal activities.

Other stocks mentioned: AMX, GILD, MNA, MRGR, NVDA, VZ
Zacks Investment Research - 4 months ago

Investors need to pay close attention to Immunomedics (IMMU) stock based on the movements in the options market lately.

Seeking Alpha - 4 months ago

Gilead Sciences Inc. (GILD) Gilead Sciences to Acquire Immunomedics Conference Call (Transcript)

Other stocks mentioned: GILD
Seeking Alpha - 4 months ago

Monoclonal Antibodies: A Good Place To Be In The Time Of Covid-19 And Stock Market Bubbles

Other stocks mentioned: BMY, CYDY, GILD, GNBT, INO, MESO, MRNA, NVAX, PFE, SRNE
Zacks Investment Research - 4 months ago

The acquisition will expand Gilead's portfolio of treatments for various types of cancer.

Other stocks mentioned: GILD
The Motley Fool - 4 months ago

It's going to be a while before we know if Gilead's $21 billion deal will pay off.

Other stocks mentioned: GILD
PRNewsWire - 4 months ago

NEW YORK, Sept. 14, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Immunomedics, Inc.

Business Wire - 4 months ago

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

InvestorPlace - 4 months ago

Immunomedics (IMMU) is seeing IMMU stock soar higher Monday following news that it will be acquired by Gilead (GILD) for $21 billion. The post Immunomedics News: IMMU Stock Skyrockets 99% on G...

Other stocks mentioned: GILD
Seeking Alpha - 4 months ago

Gilead Sciences And Immunomedics: Buy Post-Market Reaction

Other stocks mentioned: GILD
Benzinga - 4 months ago

Gilead Sciences, Inc. (NASDAQ: GILD) announced over the weekend a deal to buy Immunomedics, Inc.

Other stocks mentioned: GILD
Reuters - 4 months ago

Shares of Gilead Sciences Inc rose 3.2% on Monday, reversing their premarket losses as investors shrugged off concerns over the steep premium the U.S. drugmaker was willing to pay for Immunome...

Other stocks mentioned: GILD
Zacks Investment Research - 4 months ago

M&A Activities Intensify in Pharma Industry.

Other stocks mentioned: GILD, INCY, LLY, MRK, SGEN
Investors Business Daily - 4 months ago

Gilead Sciences drew mixed reactions from analysts after the company announced its largest acquisition ever, gaining a possible flagship cancer treatment. GILD stock rose on the news.

Other stocks mentioned: GILD
Zacks Investment Research - 4 months ago

Merck, Gilead and Lilly make progress on an otherwise slow news day.

Other stocks mentioned: GILD, INCY, LLY, MRK, SGEN
24/7 Wall Street - 4 months ago

Immunomedics Inc. (NASDAQ: IMMU) shares more than doubled on Monday after the firm announced that it would be acquired by Gilead Sciences Inc.

Other stocks mentioned: GILD
Yahoo Finance - 4 months ago

Gilead Sciences to acquire Immunomedics in $21 billion deal

Immunomedics Executive Chairman Dr.

Other stocks mentioned: GILD
Zacks Investment Research - 4 months ago

Gilead (GILD) looks to fortify its oncology portfolio with the acquisition of Immunomedics and the addition of Trodelvy to its portfolio.

Other stocks mentioned: GILD
Zacks Investment Research - 4 months ago

Immunomedics Inc. (IMMU) will be acquired by Gilead (GILD) for about $21 billion.

Other stocks mentioned: GILD
The Motley Fool - 4 months ago

Immunomedics ties the knot with Gilead Sciences in a $21 billion merger agreement.

Other stocks mentioned: GILD
Invezz - 4 months ago

Gilead Sciences Inc (NASDAQ: GILD) said late on Sunday that it will buy Immunomedics (biotech company) for £16.32 billion. The acquisition will help Gilead expand its footprint in oncology as ...

Other stocks mentioned: GILD
CNBC Television - 4 months ago

Gilead CEO Daniel O'Day on acquisition of cancer drugmaker Immunomedics

Gilead Sciences will acquire biotech company Immunomedics in a $21 billion deal that will expand Gilead's availability of cancer treatments, the companies announced on Sunday.

Other stocks mentioned: GILD
CNBC Television - 4 months ago

Gilead to buy Immunomedics, expanding cancer drug portfolio

Gilead is buying biotech company Immunomedics for $21 billion dollars.

Other stocks mentioned: GILD
Benzinga - 4 months ago

After initial reports emerged on Saturday about a potential acquisition deal, Gilead Sciences Inc (NASDAQ: GILD) confirmed that it's set to purchase Immunomedics Inc (NASDAQ: IMMU).

Other stocks mentioned: GILD
The Motley Fool - 4 months ago

The big purchase adds one of the year's most highly anticipated new cancer therapies to Gilead's product line.

Other stocks mentioned: GILD
Business Wire - 4 months ago

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Immunomedics, Inc. (NASDAQ: IMMU) to Gilead Sciences, Inc.

CNN Business - 4 months ago

Gilead Sciences will acquire biopharmaceutical company Immunomedics for $21 billion, the company announced on Sunday. The acquisition will expand Gilead's portfolio of treatments for various t...

Other stocks mentioned: GILD
CNBC - 4 months ago

Gilead Sciences will acquire biopharmaceutical company Immunomedics Inc. for $21 billion, a deal that will expand Gilead’s availability of cancer treatments, the company announced on Sunday.

Other stocks mentioned: GILD
Reuters - 4 months ago

Gilead Sciences Inc will acquire biopharmaceutical company Immunomedics Inc for $21 billion in a deal that would further expand Gilead's portfolio of cancer treatments, the companies said on S...

Other stocks mentioned: GILD
Business Wire - 4 months ago

Gilead Sciences, Inc. (Nasdaq: GILD) and Immunomedics (Nasdaq: IMMU) announced today that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Immunomed...

Other stocks mentioned: GILD
Benzinga - 4 months ago

Gilead Sciences Inc. (NASDAQ: GILD) is gearing up to purchase drug innovator Immunomedics Inc.

Other stocks mentioned: GILD
CNBC - 4 months ago

Initial partnership discussions between Gilead Sciences Inc and biopharmaceutical company Immunomedics Inc have shifted to acquisition, which would mean an expansion of Gilead’s portfolio of c...

Other stocks mentioned: GILD

About IMMU

Immunomedics, a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. It develops sacituzumab govitecan, an antibody-drug conjugate for the treatment of patients with metastatic triple-negative breast cancer. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140 for treatment of hematologic malignancies; and IMMU-130 to treat Color... [Read more...]

Industry
Biotechnology
Founded
1982
Stock Exchange
NASDAQ
Ticker Symbol
IMMU
Full Company Profile

Financial Performance

Financial Statements